AstraZeneca PLC (NASDAQ:AZN) Shares Sold by International Assets Investment Management LLC

International Assets Investment Management LLC reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 98.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,106 shares of the company's stock after selling 278,555 shares during the period. International Assets Investment Management LLC's holdings in AstraZeneca were worth $336,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Bank of Montreal Can lifted its stake in shares of AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company's stock valued at $238,397,000 after buying an additional 1,605,758 shares during the period. Franklin Resources Inc. lifted its stake in shares of AstraZeneca by 8.7% during the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company's stock worth $1,492,649,000 after purchasing an additional 1,522,715 shares during the period. Hsbc Holdings PLC boosted its holdings in shares of AstraZeneca by 750.3% during the second quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company's stock worth $100,523,000 after purchasing an additional 1,132,362 shares during the last quarter. Farallon Capital Management LLC grew its position in shares of AstraZeneca by 65.1% in the second quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company's stock valued at $187,934,000 after purchasing an additional 950,000 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in AstraZeneca in the third quarter valued at $72,437,000. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Trading Up 0.6 %

NASDAQ AZN traded up $0.43 during mid-day trading on Friday, hitting $67.01. The company's stock had a trading volume of 5,671,171 shares, compared to its average volume of 4,304,024. The firm has a market capitalization of $207.77 billion, a P/E ratio of 32.06, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The stock's fifty day simple moving average is $66.11 and its two-hundred day simple moving average is $74.86.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the business posted $0.87 EPS. The firm's revenue was up 18.0% compared to the same quarter last year. Research analysts expect that AstraZeneca PLC will post 4.11 EPS for the current year.

Analyst Upgrades and Downgrades

AZN has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, AstraZeneca has a consensus rating of "Buy" and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.